Brazil's MedTech market offers immense opportunities, but entry is governed by the complex regulations of ANVISA. This episode of MedTech Global Insights tackles the single most important decision foreign manufacturers face: choosing an ANVISA authorized representative. A poor choice can lead to a complete loss of market control, while the right partner can ensure long-term success and flexibility. We uncover the significant risks of the common practice of appointing a distributor as your representative, which can lead to your product registration being held hostage. We then detail the strategic advantages of partnering with an independent, professional firm that separates regulatory compliance from commercial interests, giving you full control over your business. Case Study Highlight: Imagine spending years building your brand in Brazil, only to realize you cannot change your underperforming distributor because they legally own your product license. You're now faced with a crippling choice: pay a fortune to buy back your own registration or abandon the market and start the multi-year approval process all over again. We explain how to avoid this costly and devastating scenario. In this episode, you will learn: - Why is the role of the ANVISA authorized representative so critical for foreign companies? - What is the biggest mistake companies make when appointing a representative in Brazil? - Who legally owns your medical device registration in Brazil, and why does it matter? - How can tying your registration to a distributor put your entire market access at risk? - What are the key advantages of using an independent, professional representative? - What responsibilities does your representative have after your product is approved? - How can technology and AI streamline the ANVISA submission and compliance process? - How do you ensure you maintain full control over your commercial strategy in Brazil? To learn more, contact us at [email protected] or visit https://pureglobal.com/.